Chimeric Therapeutics (CHM) EGM 2025 summary

Opening remarks and agenda

• Acknowledgement of traditional custodians, meeting logistics, and participation procedures were provided.

• Introduction of directors, executive management, and apologies from absent board members.

• EGM held on July 23, 2025, focused on updates in cell therapy clinical trials and corporate developments.

Board and executive committee updates

• CEO highlighted FY 2025 as her first full year, with AUD 16.6 million raised, including AUD 5.6 million from a U.S. Family Office.

• Leadership team highlighted for experience in cell therapy clinical development.

• Closure of the Lynde facility and significant headcount and cost reductions were reported.

Strategic initiatives and plans

• Updates on clinical development: CHM CDH17 trial commenced, five patients treated, dose level one completed, and dose level two underway.

• CHM Core NK product advanced to frontline setting in the advent AML study, with two out of three patients showing complete response.

• Ongoing recruitment for further patients in collaboration with MD Anderson Cancer Center.

• Multiple clinical updates anticipated in the next 12 months across four Phase 1 trials.